INVO Fertility, Inc
IVF Healthcare Medical Devices
INVO Fertility, Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.8 million, up 4.74% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS grew 100.1%, free cash flow grew 35.1% and total debt fell 50.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow IVF
INVO Fertility, Inc (IVF) P/E ratio
As of 16 October 2026, INVO Fertility, Inc (IVF) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (December 2025) to 3.5× (July 2024); the current reading is higher than 89% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | (44.44%) |
| Mar 2026 | 0.0× | (60.87%) |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 41 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NXL Nexalin Technology, Inc. compare | n/m |
| XAIR Beyond Air, Inc. compare | n/m |
| ICCM IceCure Medical Ltd. compare | n/m |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| ADGM Adagio Medical Holdings, Inc. compare | n/m |
| VJET Flyte Aviation, Inc. compare | n/m |
| BIOLQ Biolase, Inc. compare | n/m |
| IVF INVO Fertility, Inc | 0.0× |
| BJDX Bluejay Diagnostics, Inc. compare | 0.9× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)